Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Gastrointestinal Stromal Tumors Specialty Channel

Gastrointestinal Stromal Tumors
Specialty Channel
Conference Coverage
Ripretinib for Patients With Advanced GISTs in Later-Line Therapy
02/24/2023
Allison Casey
In a multicenter, retrospective study, ripretinib demonstrated clinical activity and was well-tolerated among patients with advanced gastrointestinal stromal tumors who had previously received ≥3 lines of therapy.
In a multicenter, retrospective study, ripretinib demonstrated clinical activity and was well-tolerated among patients with advanced gastrointestinal stromal tumors who had previously received ≥3 lines of therapy.
In a multicenter, retrospective...
02/24/2023
Oncology
News
Similar Survival Outcomes Between Local and Radical Excision for Rectal Gastrointestinal Stromal Tumors
01/19/2023
Allison Casey
Among patients with rectal gastrointestinal stromal tumors, local and radical excisions were found to have similar overall survival.
Among patients with rectal gastrointestinal stromal tumors, local and radical excisions were found to have similar overall survival.
Among patients with rectal...
01/19/2023
Oncology
News
Avapritinib Shows Potential for Patients With PDGRFA D842V-Mutant Gastrointestinal Stromal Tumors
12/20/2022
Allison Casey
In a phase 1/2 study, avapritinib demonstrated tolerability and anti-tumor activity in patients with gastrointestinal stromal tumors who had platelet-derived growth factor receptor alpha (PDGRFA) D842V mutations.
In a phase 1/2 study, avapritinib demonstrated tolerability and anti-tumor activity in patients with gastrointestinal stromal tumors who had platelet-derived growth factor receptor alpha (PDGRFA) D842V mutations.
In a phase 1/2 study,...
12/20/2022
Oncology
News
Laparoscopic Surgery Demonstrates Feasibility, Safety for Gastrointestinal Stromal Tumors
11/17/2022
Allison Casey
Study findings reveal laparoscopic surgery is safe and feasible for patients with gastric gastrointestinal stromal tumors sized between 5 and 8 cm, compared to open surgery.
Study findings reveal laparoscopic surgery is safe and feasible for patients with gastric gastrointestinal stromal tumors sized between 5 and 8 cm, compared to open surgery.
Study findings reveal...
11/17/2022
Oncology
News
Guadecitabine Fails to Meet Target Response Rate in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumors
11/10/2022
Phase 2 trial results reveal guadecitabine failed to yield any partial or complete responses in patients with succinate dehydrogenase deficient tumors, including gastrointestinal stromal tumors.
Phase 2 trial results reveal guadecitabine failed to yield any partial or complete responses in patients with succinate dehydrogenase deficient tumors, including gastrointestinal stromal tumors.
Phase 2 trial results reveal...
11/10/2022
Oncology
Quiz
True or False: Ripretinib demonstrated meaningful clinical activity for gastrointestinal stromal tumors after first-line imatinib.
10/18/2022
Did ripretinib demonstrate meaningful clinical activity for patients with advanced gastrointestinal stromal tumors following progression on or intolerance to first-line imatinib? Take our quiz to find out.
Did ripretinib demonstrate meaningful clinical activity for patients with advanced gastrointestinal stromal tumors following progression on or intolerance to first-line imatinib? Take our quiz to find out.
Did ripretinib demonstrate...
10/18/2022
Oncology
News
Ripretinib Provides No PFS Benefit vs Sunitinib for Patients With Advanced Gastrointestinal Stromal Tumors
09/27/2022
Allison Casey
Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE...
Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE...
Second-line treatment with...
09/27/2022
Oncology
News
Trans-Anal Total Mesorectal Excision Technique Feasible for Rectal Gastrointestinal Stromal Tumors
09/20/2022
Allison Casey
In a retrospective study, the use of trans-anal surgery using the trans-anal total mesorectal excision technique was found to be feasible for patients with rectal gastrointestinal stromal tumors.
In a retrospective study, the use of trans-anal surgery using the trans-anal total mesorectal excision technique was found to be feasible for patients with rectal gastrointestinal stromal tumors.
In a retrospective study, the...
09/20/2022
Oncology
News
Comparison of Surgical Methods for Treating Gastrointestinal Stromal Tumors
08/04/2022
Allison Casey
Findings from a comparative analysis favor endoscopic full-thickness resection and endoscopic submucosal dissection vs laparoscopic resection for patients with gastrointestinal stromal tumors.
Findings from a comparative analysis favor endoscopic full-thickness resection and endoscopic submucosal dissection vs laparoscopic resection for patients with gastrointestinal stromal tumors.
Findings from a comparative...
08/04/2022
Oncology
News
Study Identifies Factors Associated With GIST Recurrence and Metastasis
08/03/2022
Allison Casey
Primary site of tumors, tumor rupture, tumor diameter, risk grade, and mitotic figures were identified as factors associated with postoperative recurrence or metastasis in patients with GIST, according to study findings.
Primary site of tumors, tumor rupture, tumor diameter, risk grade, and mitotic figures were identified as factors associated with postoperative recurrence or metastasis in patients with GIST, according to study findings.
Primary site of tumors, tumor...
08/03/2022
Oncology
News
Preoperative Controlling Nutritional Status Score Predicts Recurrence in Patients With Resected GIST
08/03/2022
Allison Casey
Study finds high preoperative controlling nutritional status score is an independent prognostic factor for shorter recurrence-free survival among patients with resected gastrointestinal stromal tumors.
Study finds high preoperative controlling nutritional status score is an independent prognostic factor for shorter recurrence-free survival among patients with resected gastrointestinal stromal tumors.
Study finds high preoperative...
08/03/2022
Oncology

News

Conference Coverage
Ripretinib for Patients With Advanced GISTs in Later-Line Therapy
02/24/2023
Allison Casey
In a multicenter, retrospective study, ripretinib demonstrated clinical activity and was well-tolerated among patients with advanced gastrointestinal stromal tumors who had previously received ≥3 lines of therapy.
In a multicenter, retrospective study, ripretinib demonstrated clinical activity and was well-tolerated among patients with advanced gastrointestinal stromal tumors who had previously received ≥3 lines of therapy.
In a multicenter, retrospective...
02/24/2023
Oncology
News
Similar Survival Outcomes Between Local and Radical Excision for Rectal Gastrointestinal Stromal Tumors
01/19/2023
Allison Casey
Among patients with rectal gastrointestinal stromal tumors, local and radical excisions were found to have similar overall survival.
Among patients with rectal gastrointestinal stromal tumors, local and radical excisions were found to have similar overall survival.
Among patients with rectal...
01/19/2023
Oncology
News
Avapritinib Shows Potential for Patients With PDGRFA D842V-Mutant Gastrointestinal Stromal Tumors
12/20/2022
Allison Casey
In a phase 1/2 study, avapritinib demonstrated tolerability and anti-tumor activity in patients with gastrointestinal stromal tumors who had platelet-derived growth factor receptor alpha (PDGRFA) D842V mutations.
In a phase 1/2 study, avapritinib demonstrated tolerability and anti-tumor activity in patients with gastrointestinal stromal tumors who had platelet-derived growth factor receptor alpha (PDGRFA) D842V mutations.
In a phase 1/2 study,...
12/20/2022
Oncology
News
Laparoscopic Surgery Demonstrates Feasibility, Safety for Gastrointestinal Stromal Tumors
11/17/2022
Allison Casey
Study findings reveal laparoscopic surgery is safe and feasible for patients with gastric gastrointestinal stromal tumors sized between 5 and 8 cm, compared to open surgery.
Study findings reveal laparoscopic surgery is safe and feasible for patients with gastric gastrointestinal stromal tumors sized between 5 and 8 cm, compared to open surgery.
Study findings reveal...
11/17/2022
Oncology
News
Guadecitabine Fails to Meet Target Response Rate in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumors
11/10/2022
Phase 2 trial results reveal guadecitabine failed to yield any partial or complete responses in patients with succinate dehydrogenase deficient tumors, including gastrointestinal stromal tumors.
Phase 2 trial results reveal guadecitabine failed to yield any partial or complete responses in patients with succinate dehydrogenase deficient tumors, including gastrointestinal stromal tumors.
Phase 2 trial results reveal...
11/10/2022
Oncology
News
Ripretinib Provides No PFS Benefit vs Sunitinib for Patients With Advanced Gastrointestinal Stromal Tumors
09/27/2022
Allison Casey
Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE...
Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE...
Second-line treatment with...
09/27/2022
Oncology
News
Trans-Anal Total Mesorectal Excision Technique Feasible for Rectal Gastrointestinal Stromal Tumors
09/20/2022
Allison Casey
In a retrospective study, the use of trans-anal surgery using the trans-anal total mesorectal excision technique was found to be feasible for patients with rectal gastrointestinal stromal tumors.
In a retrospective study, the use of trans-anal surgery using the trans-anal total mesorectal excision technique was found to be feasible for patients with rectal gastrointestinal stromal tumors.
In a retrospective study, the...
09/20/2022
Oncology
News
Comparison of Surgical Methods for Treating Gastrointestinal Stromal Tumors
08/04/2022
Allison Casey
Findings from a comparative analysis favor endoscopic full-thickness resection and endoscopic submucosal dissection vs laparoscopic resection for patients with gastrointestinal stromal tumors.
Findings from a comparative analysis favor endoscopic full-thickness resection and endoscopic submucosal dissection vs laparoscopic resection for patients with gastrointestinal stromal tumors.
Findings from a comparative...
08/04/2022
Oncology
News
Study Identifies Factors Associated With GIST Recurrence and Metastasis
08/03/2022
Allison Casey
Primary site of tumors, tumor rupture, tumor diameter, risk grade, and mitotic figures were identified as factors associated with postoperative recurrence or metastasis in patients with GIST, according to study findings.
Primary site of tumors, tumor rupture, tumor diameter, risk grade, and mitotic figures were identified as factors associated with postoperative recurrence or metastasis in patients with GIST, according to study findings.
Primary site of tumors, tumor...
08/03/2022
Oncology
News
Preoperative Controlling Nutritional Status Score Predicts Recurrence in Patients With Resected GIST
08/03/2022
Allison Casey
Study finds high preoperative controlling nutritional status score is an independent prognostic factor for shorter recurrence-free survival among patients with resected gastrointestinal stromal tumors.
Study finds high preoperative controlling nutritional status score is an independent prognostic factor for shorter recurrence-free survival among patients with resected gastrointestinal stromal tumors.
Study finds high preoperative...
08/03/2022
Oncology

Interactive Features

Quiz
True or False: Ripretinib demonstrated meaningful clinical activity for gastrointestinal stromal tumors after first-line imatinib.
10/18/2022
Did ripretinib demonstrate meaningful clinical activity for patients with advanced gastrointestinal stromal tumors following progression on or intolerance to first-line imatinib? Take our quiz to find out.
Did ripretinib demonstrate meaningful clinical activity for patients with advanced gastrointestinal stromal tumors following progression on or intolerance to first-line imatinib? Take our quiz to find out.
Did ripretinib demonstrate...
10/18/2022
Oncology
Test Your Knowledge
Quiz: Is There Indication of Decreasing Prevalence of GISTs?
02/24/2022
True or false: Acknowledging GISTs are the most common sarcoma of the GI tract, with estimated incidence between 1.0 and 1.5/100,000 per year, current estimates suggest prevalence decreasing incidences. 
True or false: Acknowledging GISTs are the most common sarcoma of the GI tract, with estimated incidence between 1.0 and 1.5/100,000 per year, current estimates suggest prevalence decreasing incidences. 
True or false: Acknowledging...
02/24/2022
Oncology
Test Your Knowledge
Quiz: Recommended Treatment Options for c-KIT, PDGFRA Wild-Type GIST
02/18/2022
True or false: Typically, clinical trials or targeted therapies are recommended for patients with c-KIT and PDGFRA wild-type GIST who are unable to obtain multi-target protein tyrosine kinase inhibitors therapy.
True or false: Typically, clinical trials or targeted therapies are recommended for patients with c-KIT and PDGFRA wild-type GIST who are unable to obtain multi-target protein tyrosine kinase inhibitors therapy.
True or false: Typically,...
02/18/2022
Oncology
Quiz
Quiz: Which Diagnosis Method Provides Better Aid for Patients with GIST?
08/11/2021
Which method is confirmed to provide better aid in the diagnosis of GIST therapy?
Which method is confirmed to provide better aid in the diagnosis of GIST therapy?
Which method is confirmed to...
08/11/2021
Oncology
Quiz
Quiz: Is There a Correlation Between High-Risk GIST and Chromosomal Complexity?
08/10/2021
True or false: In localized, high-risk GIST, patients with chromosomal complexities have poor RFS.
True or false: In localized, high-risk GIST, patients with chromosomal complexities have poor RFS.
True or false: In localized,...
08/10/2021
Oncology
Interactive Features
Quiz: Are There Possible Clinical Differences in Multiple Vs Single GISTs?
06/02/2021
True or False: Findings from a retrospective analysis suggest the clinical features and treatment approaches for multiple gastrointestinal stromal tumors (MGISTs) may differ from single GISTs, ultimately presenting a gap in the treatment...
True or False: Findings from a retrospective analysis suggest the clinical features and treatment approaches for multiple gastrointestinal stromal tumors (MGISTs) may differ from single GISTs, ultimately presenting a gap in the treatment...
True or False: Findings from a...
06/02/2021
Oncology
Test Your Knowledge
Quiz: Genetic Vs Sporadic Diagnosis in GIST
05/03/2021
True or False: A genetic diagnosis yields benefit in gastrointestinal stromal tumor therapy by informing the patient and provider(s) of the possibility for other malignancies, suggested surveillance, management for other NF1 comorbidities,...
True or False: A genetic diagnosis yields benefit in gastrointestinal stromal tumor therapy by informing the patient and provider(s) of the possibility for other malignancies, suggested surveillance, management for other NF1 comorbidities,...
True or False: A genetic...
05/03/2021
Oncology
Test Your Knowledge
Quiz: How is Ripretinib Designed to Treat GIST?
04/07/2021
True or false: Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of KIT and PDGFRA mutations.
True or false: Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of KIT and PDGFRA mutations.
True or false: Ripretinib is a...
04/07/2021
Oncology
Test Your Knowledge
Quiz: Adjuvant Imatinib for High-Risk GIST
03/29/2021
True or false: Prolonged adjuvant imatinib therapy extends overall survival in patients with high-risk GIST.
True or false: Prolonged adjuvant imatinib therapy extends overall survival in patients with high-risk GIST.
True or false: Prolonged...
03/29/2021
Oncology
Test Your Knowledge
Quiz: Treatment Options for Stage IV GIST
02/09/2021
Which of the following combination treatment options has yielded the best outcomes in patients with stage IV GIST?
Which of the following combination treatment options has yielded the best outcomes in patients with stage IV GIST?
Which of the following...
02/09/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Similar Survival Outcomes Between Local and Radical Excision for Rectal Gastrointestinal Stromal Tumors
01/19/2023
Allison Casey
Among patients with rectal gastrointestinal stromal tumors, local and radical excisions were found to have similar overall survival.
Among patients with rectal gastrointestinal stromal tumors, local and radical excisions were found to have similar overall survival.
Among patients with rectal...
01/19/2023
Oncology
News
Avapritinib Shows Potential for Patients With PDGRFA D842V-Mutant Gastrointestinal Stromal Tumors
12/20/2022
Allison Casey
In a phase 1/2 study, avapritinib demonstrated tolerability and anti-tumor activity in patients with gastrointestinal stromal tumors who had platelet-derived growth factor receptor alpha (PDGRFA) D842V mutations.
In a phase 1/2 study, avapritinib demonstrated tolerability and anti-tumor activity in patients with gastrointestinal stromal tumors who had platelet-derived growth factor receptor alpha (PDGRFA) D842V mutations.
In a phase 1/2 study,...
12/20/2022
Oncology
News
Laparoscopic Surgery Demonstrates Feasibility, Safety for Gastrointestinal Stromal Tumors
11/17/2022
Allison Casey
Study findings reveal laparoscopic surgery is safe and feasible for patients with gastric gastrointestinal stromal tumors sized between 5 and 8 cm, compared to open surgery.
Study findings reveal laparoscopic surgery is safe and feasible for patients with gastric gastrointestinal stromal tumors sized between 5 and 8 cm, compared to open surgery.
Study findings reveal...
11/17/2022
Oncology
News
Guadecitabine Fails to Meet Target Response Rate in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumors
11/10/2022
Phase 2 trial results reveal guadecitabine failed to yield any partial or complete responses in patients with succinate dehydrogenase deficient tumors, including gastrointestinal stromal tumors.
Phase 2 trial results reveal guadecitabine failed to yield any partial or complete responses in patients with succinate dehydrogenase deficient tumors, including gastrointestinal stromal tumors.
Phase 2 trial results reveal...
11/10/2022
Oncology
News
Ripretinib Provides No PFS Benefit vs Sunitinib for Patients With Advanced Gastrointestinal Stromal Tumors
09/27/2022
Allison Casey
Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE...
Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE...
Second-line treatment with...
09/27/2022
Oncology
News
Trans-Anal Total Mesorectal Excision Technique Feasible for Rectal Gastrointestinal Stromal Tumors
09/20/2022
Allison Casey
In a retrospective study, the use of trans-anal surgery using the trans-anal total mesorectal excision technique was found to be feasible for patients with rectal gastrointestinal stromal tumors.
In a retrospective study, the use of trans-anal surgery using the trans-anal total mesorectal excision technique was found to be feasible for patients with rectal gastrointestinal stromal tumors.
In a retrospective study, the...
09/20/2022
Oncology
News
Comparison of Surgical Methods for Treating Gastrointestinal Stromal Tumors
08/04/2022
Allison Casey
Findings from a comparative analysis favor endoscopic full-thickness resection and endoscopic submucosal dissection vs laparoscopic resection for patients with gastrointestinal stromal tumors.
Findings from a comparative analysis favor endoscopic full-thickness resection and endoscopic submucosal dissection vs laparoscopic resection for patients with gastrointestinal stromal tumors.
Findings from a comparative...
08/04/2022
Oncology
News
Study Identifies Factors Associated With GIST Recurrence and Metastasis
08/03/2022
Allison Casey
Primary site of tumors, tumor rupture, tumor diameter, risk grade, and mitotic figures were identified as factors associated with postoperative recurrence or metastasis in patients with GIST, according to study findings.
Primary site of tumors, tumor rupture, tumor diameter, risk grade, and mitotic figures were identified as factors associated with postoperative recurrence or metastasis in patients with GIST, according to study findings.
Primary site of tumors, tumor...
08/03/2022
Oncology
News
Preoperative Controlling Nutritional Status Score Predicts Recurrence in Patients With Resected GIST
08/03/2022
Allison Casey
Study finds high preoperative controlling nutritional status score is an independent prognostic factor for shorter recurrence-free survival among patients with resected gastrointestinal stromal tumors.
Study finds high preoperative controlling nutritional status score is an independent prognostic factor for shorter recurrence-free survival among patients with resected gastrointestinal stromal tumors.
Study finds high preoperative...
08/03/2022
Oncology
News
Bridging Study Finds Ripretinib Improves Survival Among Chinese Patients With Advanced Gastrointestinal Stromal Tumors
07/08/2022
Allison Casey
In a phase 2 bridging study of the phase 3 INVICTUS study, ripretinib was found to improve the survival of Chinese patients with advanced gastrointestinal stromal tumors.
In a phase 2 bridging study of the phase 3 INVICTUS study, ripretinib was found to improve the survival of Chinese patients with advanced gastrointestinal stromal tumors.
In a phase 2 bridging study of...
07/08/2022
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement